Abbott Laboratories & Sun Pharma
7 shared events · Importance 3 · Last updated Mar 31, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Abbott Laboratories competes directly with Sun Pharma in the global pharmaceutical market, particularly within branded generics and emerging markets.
Business
Abbott Laboratories: Abbott Laboratories>>> is partnered with Alvogen>>> for AVT03, a different biosimilar. While not directly involved in the current resubmissions, their partnership with Alvogen>>> indicates a broader strategy in the biosimilar market.
Sun Pharma: Sun Pharma>>> is partnered with Alvogen>>> for the commercialization of AVT05 and AVT06. The resubmission of BLAs by Alvogen>>> is a positive development for Sun Pharma>>> as it moves closer to potentially commercializing these biosimilars.
Jun 04, 2026 · 10 articles
Regulatory
Abbott Laboratories: Dr. Reddy's produces lower-cost generic semaglutide; the approval may pressure its market share in the obesity segment.
Sun Pharma: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
Business
Abbott Laboratories: Abbott Laboratories is one of several Indian generic drugmakers poised to enter the market with lower-priced versions of semaglutide once Semaglutide loses patent exclusivity.
Sun Pharma: Sun Pharma is among the Indian generic drugmakers expected to introduce lower-priced versions of semaglutide after Semaglutide's patent expires.
Nov 11, 2025 · 6 articles
International
Abbott Laboratories: Fell among top losers, possibly due to tariff concerns.
Sun Pharma: Gained as a top gainer.
Jul 06, 2026 · 105 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Abbott Laboratories and Sun Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard